Our data additionally highlight the potential utility of low CD45RA+ (<20% CD4+ cells) in subcategorizing CVID patients at risk for lymphoproliferative complications including LAD, granulomas, autoimmune hepatitis, and GLILD. This evidence concerns the gene CD4 and autoimmune hepatitis.